Humanized mice (target-specific)

Well-established mouse lines that allow in vivo efficacy and safety assessment of biologics and other compounds.

Applications & Features

Target-specific humanized models provide a robust platform for advancing drug development and therapeutic research across a wide range of biomedical fields, including oncology, immunology, and inflammation.

These models enable predictive and translational preclinical research, supporting diverse applications such as:

  • Evaluating the efficacy of T-cell engagers (e.g., Pan hCD3 model), biologics, and small molecules (e.g., hTFRC)
  • Investigating immune checkpoints and assessing them as potential drug targets (e.g., hPD-1 and hVISTA)
  • Testing antibody-dependent therapies (e.g., hFcgR)
  • Conducting pharmacokinetic (PK) analysis (e.g., HSA/hFcRn)

Immunocompetent and free from murine target gene expression, the models exhibit physiological, human-like target expression while preserving critical cell/cell and ligand/target interactions. These features make them an invaluable resource for syngeneic studies.

Discover our

Humanized mice (target-specific)

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

hCD137

hCD137 immunocompetent mice enable the efficacy assessment of anti-CD137

No items found.

hCD28

The hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

Immune checkpoint
CD28
ICP (single-target)
T-cell engager

genO-hPD-1/hGITR/hGITRL

The genO-hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

Immune checkpoint
PD-1
GITR
ICP (multi-target)
GITRL

hIgE/hFcεR1

Use the hIgE/hFcεR1 mouse model to successfully screen for innovative therapeutics for allergy, asthma and other IgE-mediated diseases.

Inflammation
IgE
FceR1
Fc receptor
Allergy

hPD-1/hTIM3

The hPD-1/hTIM3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice.

Immune checkpoint
PD-1
TIM3
ICP (multi-target)

hPD-1/hVISTA

The hPD-1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

Immune checkpoint
PD-1
VISTA
ICP (multi-target)

hGLP-1R

Preclinical hGLP-1R model for assessment of agents targeting human GLP-1R

GLP-1R
Metabolism

hCTLA-4/hLAG3

The hCTLA-4/hLAG3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
Lag3
ICP (multi-target)

HSA/hFcRn-Rag1-KO

This upgraded, immunocompromised Rag1-/- version of our HSA/hFcRn mouse model allows the assessment of compounds' half-life and anti-tumor efficacy in a human tumor model.

HSA
PK/PD
Fc receptor
KO-Rep-Mix

hCD3ε/hCD28

hCD3ε  immunocompetent mice enable the efficacy assessment of T-cell engagers, to  study cancer cell recognition, immunosuppressant therapies, etc.

CD3
CD28
T-cell engager

hGITR

The hGITR mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR in fully immunocompetent mice.

Immune checkpoint
GITR
ICP (single-target)

hCTLA-4

The hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
ICP (single-target)

hCD4

The human CD4 mouse model allows in vivo efficacy and safety assessment of anti-human CD4 compounds.

CD4
Inflammation
T-cell receptor

hTNF-α

The hTNF-α model provides new opportunities for assessment of anti-TNF therapies.

Inflammation
TNF
Cytokine

hFcγR

Preclinical humanized Fc-gamma receptor (hFcγR) model enabling the assessment of Fc receptor pathways targeted therapies.

FcgR
Fc receptor

hPD-1/hCTLA-4

The hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
PD-1
ICP (multi-target)

hGITR/hGITRL

The hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of agonist and antagonist antibodies targeting human immune checkpoint GITR and/or GITRL in fully immunocompetent mice.

Immune checkpoint
GITR
GITRL
ICP (multi-target)

hcGAS

The hcGAS mouse enables the in vivo assessment of agents and therapies targeting the cGAS–STING cytosolic DNA sensing pathway in fully immunocompetent mice.

cGAS
cGAS-STING pathway

Discover our customized models

Learn  more

Related resources and publications

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No results